Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1934472 | 0.93 | GPR119 (0.51) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL21456062 | 0.87 | HPGD (0.58) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL2773515 | 0.85 | EPHX1 (0.61) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL13128796 | 0.85 | GPR119 (0.54) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL15015360 | 0.84 | EPHX1 (0.54) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL2770208 | 0.83 | GPR119 (0.61) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL31543231 | 0.82 | GPR119 (0.54) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL31482200 | 0.81 | HPGD (0.47) | HPGDGPR119EPHX1SMN1; SMN2RECQL | |
| SCHEMBL1934050 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2CYP2D6HTT | |
| SCHEMBL31561531 | 0.80 | GPR119 (0.52) | HPGDGPR119EPHX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-8623859-B2 | Bradykinin B1 antagonists | EVOTEC AG (DE) | 2014-01-07 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| WO-2010020556-A1 | NEW BRADYKININ B1 ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073627-A1 | BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | HPGD 540/4885GPR119 460/4885EPHX1 680/4885 |
| US-20110201589-A1 | NEW BRADYKININ B1 ANTAGONISTS | BDKRB1, BDKRB2, BRS3 | HPGD 577/4885GPR119 405/4885EPHX1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.